These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 18465327)

  • 21. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
    Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
    Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features of incident cases, Palermo Province, 2002-2004 .
    Zarcone M; Amodio R; Campisi I; Cusimano R; Dolcemascolo C; Miceli V; Traina A; Macaluso M
    Ann N Y Acad Sci; 2009 Feb; 1155():222-6. PubMed ID: 19250207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas.
    Valkov A; Sorbye S; Kilvaer TK; Donnem T; Smeland E; Bremnes RM; Busund LT
    Int J Oncol; 2011 Apr; 38(4):1031-40. PubMed ID: 21271213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience.
    Faratian D; Kay C; Robson T; Campbell FM; Grant M; Rea D; Bartlett JM
    Histopathology; 2009 Nov; 55(5):587-93. PubMed ID: 19912364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma in situ.
    Quintayo MA; Starczynski J; Yan FJ; Wedad H; Nofech-Mozes S; Rakovitch E; Bartlett JM
    Histopathology; 2014 Jul; 65(1):2-8. PubMed ID: 24267587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
    Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
    Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.
    Hanley KZ; Birdsong GG; Cohen C; Siddiqui MT
    Cancer; 2009 Aug; 117(4):279-88. PubMed ID: 19551847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical evaluation of estrogen and progesterone receptors in paraffin-embedded, formalin-fixed endometrial tissues: comparison with enzyme immunoassay and immunohistochemical analysis of frozen tissue.
    Ravn V; Havsteen H; Thorpe SM
    Mod Pathol; 1998 Aug; 11(8):709-15. PubMed ID: 9720497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.
    Dakin Haché K; Gray S; Barnes PJ; Dewar R; Younis T; Rayson D
    Breast Cancer Res Treat; 2007 Oct; 105(2):169-75. PubMed ID: 17268818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c.
    Kyndi M; Sørensen FB; Knudsen H; Alsner J; Overgaard M; Nielsen HM; Overgaard J
    Acta Oncol; 2008; 47(4):608-17. PubMed ID: 18465329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.
    Müller BM; Kronenwett R; Hennig G; Euting H; Weber K; Bohmann K; Weichert W; Altmann G; Roth C; Winzer KJ; Kristiansen G; Petry C; Dietel M; Denkert C
    Diagn Mol Pathol; 2011 Mar; 20(1):1-10. PubMed ID: 21326033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer.
    Tramm T; Kyndi M; Sørensen FB; Overgaard J; Alsner J
    Acta Oncol; 2018 Jan; 57(1):102-106. PubMed ID: 29202620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
    Hanley KZ; Siddiqui MT; Lawson D; Cohen C; Nassar A
    Diagn Cytopathol; 2009 Apr; 37(4):251-7. PubMed ID: 19217031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.
    Harigopal M; Heymann J; Ghosh S; Anagnostou V; Camp RL; Rimm DL
    Breast Cancer Res Treat; 2009 May; 115(1):77-85. PubMed ID: 18521745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of tissue microarray technology in endometrioid cancer of the endometrium.
    Fons G; Hasibuan SM; van der Velden J; ten Kate FJ
    J Clin Pathol; 2007 May; 60(5):500-3. PubMed ID: 16822874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-throughput immunophenotyping of 43 ferret lymphomas using tissue microarray technology.
    Hammer AS; Williams B; Dietz HH; Hamilton-Dutoit SJ
    Vet Pathol; 2007 Mar; 44(2):196-203. PubMed ID: 17317796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.
    Bhargava R; Lal P; Chen B
    Diagn Mol Pathol; 2004 Dec; 13(4):213-6. PubMed ID: 15538111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
    Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
    Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.